Ipsen, Skyhawk Therapeutics To Develop RNA-Modulating Molecules For Rare Neurological Disorders
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – French biopharmaceutical company Ipsen SA (IPSEY) and Skyhawk Therapeutics announced an exclusive worldwide collaboration aimed at discovering and developing novel small molecules capable of modulating RNA for rare neurological diseases.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1939997662-e0926c3b7ea34d6295c885a77fba381d.jpg "10 Myths About Traditional IRAs That Could Be Hurting Your Retirement Savings")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1980166648-68686d06bb6d4315ad3d6d24bef206b5.jpg "The Unexpected Ways Your Health Influences Happiness in Retirement")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1820110452-06a5eac2d38c4fc3b601c834d343e1e9.jpg "How Required Minimum Distributions Impact Your Traditional IRA Balance")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1092093268-80a57498263449618de3d6c9ae9421cb.jpg "When Is It a Good Idea to Use ILIT Trust?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1978625622-8f9bb3f8e3b045c1b960921e5482ebea.jpg "How to Start Saving for a House")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-14922896821-6ef015efaf9b49dea9a6603ee12494f1.jpg "New Year, New Wealth: 5 Strategic Resolutions Every Investor Should Follow")